Literature DB >> 30307334

The combined administration of parthenolide and ginsenoside CK in long circulation liposomes with targeted tLyp-1 ligand induce mitochondria-mediated lung cancer apoptosis.

Xin Jin1,2, Jianping Zhou2, Zhenhai Zhang3, Huixia Lv2.   

Abstract

BACKGROUND: Combinations of natural products with low toxicities using tumor-targeting carriers may improve cancer treatment. The combined parthenolide and ginsenoside compound K (CK) within tLyp-1 liposomes, with the aim of improving the efficacy of lung cancer treatment.
RESULTS: In vitro studies in A549 human pulmonary adenocarcinoma cells demonstrated that parthenolide/CK tLyp-1 liposomes increased reactive oxygen species levels and induced mitochondrial apoptosis. It enters into cells via receptor-mediated uptake and micropinocytosis, followed by endosomal/lysosomal escape. In vivo studies illustrated that it produced a greater antitumor effect than combined administration of these compounds, with minimal toxicity.
CONCLUSION: The findings of this study indicated that combined application of natural products in nanocarriers could offer attractive therapeutic options.

Entities:  

Keywords:  Combined administration; ginsenoside CK; lung cancer; natural products; parthenolide; tLyp-1 liposomes

Mesh:

Substances:

Year:  2018        PMID: 30307334     DOI: 10.1080/21691401.2018.1518913

Source DB:  PubMed          Journal:  Artif Cells Nanomed Biotechnol        ISSN: 2169-1401            Impact factor:   5.678


  16 in total

1.  Parthenolide inhibits the proliferation and induces the apoptosis of human uveal melanoma cells.

Authors:  Song-Tian Che; Li Bie; Xu Li; Hui Qi; Peng Yu; Ling Zuo
Journal:  Int J Ophthalmol       Date:  2019-10-18       Impact factor: 1.779

Review 2.  Anticancer activities of phytoconstituents and their liposomal targeting strategies against tumor cells and the microenvironment.

Authors:  Jing Zhang; Xiang Li; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2020-05-28       Impact factor: 15.470

Review 3.  Gut Microbiota: Therapeutic Targets of Ginseng Against Multiple Disorders and Ginsenoside Transformation.

Authors:  Zhaoqiang Chen; Zepeng Zhang; Jiaqi Liu; Hongyu Qi; Jing Li; Jinjin Chen; Qingxia Huang; Qing Liu; Jia Mi; Xiangyan Li
Journal:  Front Cell Infect Microbiol       Date:  2022-04-25       Impact factor: 6.073

Review 4.  Plant-Derived Natural Products in Cancer Research: Extraction, Mechanism of Action, and Drug Formulation.

Authors:  Wamidh H Talib; Izzeddin Alsalahat; Safa Daoud; Reem Fawaz Abutayeh; Asma Ismail Mahmod
Journal:  Molecules       Date:  2020-11-14       Impact factor: 4.411

Review 5.  Ginsenoside Compound K: Insights into Recent Studies on Pharmacokinetics and Health-Promoting Activities.

Authors:  Anshul Sharma; Hae-Jeung Lee
Journal:  Biomolecules       Date:  2020-07-10

6.  A smart viral vector for targeted delivery of hydrophobic drugs.

Authors:  Sukanya Ghosh; Manidipa Banerjee
Journal:  Sci Rep       Date:  2021-03-29       Impact factor: 4.379

Review 7.  Application of Nanoparticles in the Treatment of Lung Cancer With Emphasis on Receptors.

Authors:  Jingyue Wang; Tong Zhou; Ying Liu; Shuangmin Chen; Zhenxiang Yu
Journal:  Front Pharmacol       Date:  2022-01-10       Impact factor: 5.810

Review 8.  Ginsenosides emerging as both bifunctional drugs and nanocarriers for enhanced antitumor therapies.

Authors:  Hong Wang; Yu Zheng; Qiang Sun; Zhen Zhang; Mengnan Zhao; Cheng Peng; Sanjun Shi
Journal:  J Nanobiotechnology       Date:  2021-10-15       Impact factor: 10.435

Review 9.  The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy.

Authors:  Tao An; Huanhuan Yin; Yanting Lu; Feng Liu
Journal:  Drug Des Devel Ther       Date:  2022-04-29       Impact factor: 4.319

Review 10.  Anticancer Activities of Ginsenosides, the Main Active Components of Ginseng.

Authors:  Heeok Hong; Delgerzul Baatar; Seong Gu Hwang
Journal:  Evid Based Complement Alternat Med       Date:  2021-02-03       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.